OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy

N/ANot Yet RecruitingNCT06399172

OncoSil Medical Limited50 enrolled

Overview

The OSPRItaly Patient Registry has been developed to assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, within a real-world observational registry.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Locally Advanced Pancreatic Adenocarcinoma

Interventions

OncoSilDEVICE

Intra-tumoural implantation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients who are eligible for and undergo OncoSil™ implantation at an eligible treatment facility according to the approved OncoSil™ System Instructions for Use (IFU), as part of their clinical care. 2. Patients who have completed and signed the Patient Informed Consent Form (PICF) for the OSPRItaly Patient Registry. Exclusion Criteria: 1. Patients participating in an interventional clinical study (company or investigator-sponsored). 2. Use of an investigational agent at the time of enrolment.

Outcomes

Primary Outcomes

Safety and tolerability

The analysis for safety within the real-world setting will be performed. The safety of OncoSil™ is defined by the Adverse Event profile. All safety summaries will be produced for the Intention-To-Treat (ITT) population. Adverse Device Effects will be coded using Medical Dictionary for Regulatory Activities (MedDRA). All Adverse Device Effects recorded during the Registry will be listed. Summary tables will be produced for Treatment Emergent Adverse Device Effects (TEADEs). The number and percentage of patients with device-related Adverse Events by system organ class (SOC) and preferred term will be tabulated. Similar summaries will be produced by severity of event (both mild, moderate or severe, CTCAE grade 1-4) and device relationship. In addition, summary tables will be produced for serious TEADEs and TEADEs associated with special interest acute/late radiation effects and or withdrawal.

Time frame: Followed to death or to 24-months after the date of the last enrolled patient.

Tumour response

Target (implanted) tumour response (local and distant)

Time frame: 1 year

Device implantation Performance

Safety of the implantation of OncoSil™ within the target tumour will be measured by means of procedure-related Adverse Events. Ease of administration and implantation related data from user questionnaires will be assessed.

Time frame: 1 year

Overall Survival

Overall survival (OS) is defined as the time from enrolment to the date of death from any cause. Patients who are alive or permanently lost to follow-up at the cut-off date for the analysis will be censored at the last date the patient was known to be alive.

Time frame: Followed to death or to 24-months after the date of the last enrolled patient

Resection Rates

Surgical resection rates and outcome

Time frame: Followed to death or 24 months after the date of the last enrolled patient

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.